retatrutide phase 2 results obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Phase 2 NEJM Trial:

People who lost 30 pounds in 8 weeks post about it

Tirzepatide is not indicated for patients with type 1 diabetes

This study, which focused on adults with Type 2 diabetes, showed that retatrutide achieved an average A1C reduction of up to 2.0% and significant body weight loss in just 40 weeks

Retatrutide and Tirzepatide | Dosage Comparison | Research Only Retatrutide and tirzepatide have similar dosing schedules due to their related pharmacokinetic properties

How effective is retatrutide for subcutaneous fat loss

Brand-name medications are prescribed when appropriate, and compounded options may be available through licensed 503A pharmacies